Clinical Study

Contraceptive Use and Associated Factors among Women Enrolling into HIV Care in Southwestern Uganda

Winnie Muyindike, Robin Fatch, Rachel Steinfield, Lynn T. Matthews, Nicholas Musinguzi, Nneka I. Emenyonu, Jeffrey N. Martin, and Judith A. Hahn

1 Department of Internal Medicine, Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda
2 Department of Internal Medicine, Mbarara Regional Referral Hospital, P.O. Box 1410, Mbarara, Uganda
3 Department of Medicine, University of California, San Francisco, P.O. Box 0886, CA 94143, USA
4 Department of Obstetrics, Gynecology, and Reproductive Services, University of California, San Francisco, CA 94143, USA
5 Division of Infectious Diseases and Center for Global Health, Massachusetts General Hospital, Boston, MA 02114, USA
6 Division of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
7 Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94107, USA

Correspondence should be addressed to Judith A. Hahn, jhahn@epi-center.ucsf.edu

Received 5 July 2012; Accepted 28 August 2012

Academic Editor: Consuelo Beck Sague

Background. Preventing unintended pregnancies among women living with HIV is an important component of prevention of mother-to-child HIV transmission (PMTCT), yet few data exist on contraceptive use among women entering HIV care. Methods. This was a retrospective study of electronic medical records from the initial HIV clinic visits of 826 sexually active, nonpregnant, 18–49-year old women in southwestern Uganda in 2009. We examined whether contraceptive use was associated with HIV status disclosure to one’s spouse. Results. The proportion reporting use of contraception was 27.8%. The most common method used was injectable hormones (51.7%), followed by condoms (29.6%), and oral contraceptives (8.7%). In multivariable analysis, the odds of contraceptive use were significantly higher among women reporting secondary education, higher income, three or more children, and younger age. There were no significant independent associations between contraceptive use and HIV status disclosure to spouse. Discussion. Contraceptive use among HIV-positive females enrolling into HIV care in southwestern Uganda was low. Our results suggest that increased emphasis should be given to increase the contraception uptake for all women especially those with lower education and income. HIV clinics may be prime sites for contraception education and service delivery integration.

1. Introduction

Sub-Saharan Africa has the highest prevalence and incidence of HIV-1 infection in the world [1]. Women of reproductive age account for 60 percent of all adult infections and 75 percent of infections among people 15–24 years old [2]. Sub-Saharan Africa also has high fertility rates with an estimated 14 million unintended pregnancies annually [3]. In 2008, the number of children newly infected with HIV was approximately 430,000, of which 90 percent were infected through mother-to-child transmission (MTCT) [4]. The World Health Organization (WHO) lists preventing unintended pregnancies among people living with HIV as a second pillar of preventing mother-to-child transmission (PMTCT) [4]. Not only is preventing unintended pregnancies in HIV-infected women an effective strategy for reducing perinatal transmission [5–8], but it is also cost saving [8, 9] and would contribute to the reduction of maternal mortality, which may be higher among HIV-infected women [10–12]. However, most PMTCT efforts to date prioritize the provision of antiretroviral (ARV) prophylaxis to HIV infected pregnant women, their infants, and safer breastfeeding strategies [4, 13, 14].

In Uganda, HIV-1 seroprevalence among adults is 6.5%, and 57% of the HIV-positive adults are women [1]. The total fertility rate (TFR) in Uganda is 6.7 children per woman
and among the highest worldwide [15]. An estimated 24% of married women in Uganda use contraceptive methods, with an unmet need for contraception of 41% among women of reproductive age [15]. MTCT of HIV contributes 20% of new HIV infections in Uganda, although PMTCT services provide 60% of pregnant women living with HIV with ARV prophylaxis [16]. Many HIV-positive women have unintended pregnancies [17–20] with a concomitant risk of MTCT; however, the risk is greatly diminished if ARV prophylaxis is initiated early in pregnancy [21]. A modeling study in Uganda showed that contraception has the potential to avert twice the number of vertical HIV infections and pediatric AIDS deaths as compared to PMTCT interventions initiated among already pregnant women living with HIV [7]. Reports show that living with HIV may be associated with a desire to limit child bearing [22]; on the other hand, fertility desires may increase with access to HIV treatment [23, 24]. Several Ugandan reports suggest that, among women in HIV care, the most common contraceptive method reported is condom use [17, 20, 25], which has a high contraceptive failure rate [26].

Little is known about contraceptive use among HIV positive women entering HIV care in Uganda, a country in which access to reproductive health care is limited [27]. Entry into HIV care may represent an opportune time to assess women's fertility plans and intervene to prevent unintended pregnancies and reduce MTCT of HIV. We therefore conducted a retrospective analysis of electronic medical records from initial visits to a large HIV clinic in southwestern Uganda to document the use of contraception among women of reproductive age. In addition, we examined correlates of contraceptive use with the goal of informing strategies to increase the uptake of contraception. We sought to determine whether HIV disclosure to one's spouse and other sexual partners was associated with increased contraceptive use, because this factor has previously been shown to be correlated with increased condom use, and decreased sexual risk behavior, in Uganda and other countries in Sub-Saharan Africa [20, 28–32]. We also examined demographic characteristics as possible confounders.

### 2. Methods

#### 2.1. Setting and Study Population

Our sample included HIV-positive women of reproductive age (18–49 years) who enrolled into the Mbarara Regional Hospital HIV clinic (also known as the Immune Suppression Syndrome (ISS) clinic) during 2009. Mbarara Regional Referral Hospital serves a population of 2.5 million people in southwestern Uganda. As of December 2009, the ISS clinic, which provides free HIV care, had 7500 active adult (age 18 and older) HIV-positive clients, 4500 of whom were women. The total number of adult clients receiving antiretroviral therapy (ART) by the end of 2009 was 5300. We excluded pregnant women, those who reported sexual abstinence, and women over age 49 from the analysis. We chose the cutoff of age 49 to be consistent with reproductive health data reported in the Uganda Demographic and Health Survey (UDHS) report [15].

#### 2.2. Data Collection

Data for this study were abstracted from patient records that are routinely collected at the initial ISS Clinic visit. Data are collected on standard forms adapted from the Open Medical Records System (Open MRS) framework developed by Moi University and Indiana University for use in developing countries. The ISS Clinic enrollment visit form includes sociodemographic and behavioral data, including contraception use (collected by counselors and nursing officers) and clinical information (collected by physicians). The data from this form are entered into the Open MRS data management system by data clerks. Regular quality control checks are performed on 5% of entered records by comparing each variable with the original source document: entry errors occur in less than 1% of the data but omission of data from several variables on the form is frequent (see below).

#### 2.3. Measurements

##### 2.3.1. Outcome Variable

The outcome variable was self-reported use of one or more contraceptive methods at enrollment into care. The methods extracted from the electronic Open MRS included hormonal methods (combined oral contraceptives (COCs), injectable hormones including depot medroxyprogesterone acetate (DPMA), and implants), as well as nonhormonal methods (male condoms, diaphragms, cervical caps, intrauterine devices (IUDs), natural rhythm methods), and sterilization methods (bilateral tubal ligation and hysterectomy). We categorized hormone-based contraception (injection, implant, or pill), IUDs, or sterilization methods as highly effective. Other contraceptive methods available in Uganda but not captured in the electronic data include progesterin only pills and emergency contraceptives.

##### 2.3.2. Independent Variables

The main covariate of interest was self-reported disclosure of HIV status to a spouse or sexual partner(s) at the initial clinic visit. The disclosure variable captured whether a woman had disclosed to a spouse or sexual partner, had disclosed to someone other than a spouse or partner, or had not disclosed. Other independent variables included age, marital status (“married” was defined as legal or common-law marriage), number of children, education level, monthly income, religion, WHO clinical stage, CD4 cell count, and spouse’s HIV status.

#### 2.4. Statistical Methods

We evaluated records of 1110 females of reproductive age (18–49 years) who presented to the ISS clinic from January to December 2009. 210 were either pregnant (151; 13.6%) or reported current sexual abstinence (59; 5.7%) at their initial visit and were excluded, and further 74 (6.7%) were missing data on contraceptive use and were also excluded, leaving 826 women for analysis. Women who were missing data on contraception were less likely to be currently married (34.4%) compared to those who were not missing contraception data (48.5% married,
The Institutional Review Boards which the HIV status of the women had been disclosed and condom use was more common among partnerships in comparison to other contraception methods, primarily spouse or a sexual partner. We also examined condom use using a composite variable representing disclosure to either a spouse or sexual partner, 71% disclosed to someone else, and 26% disclosed to no one. Most women were enrolled within 3 months of HIV diagnosis (72%) with mild HIV-associated symptoms placing them in WHO HIV clinical stages 1 or 2 (64%), and few (7%) were on ART at clinic entry, presumably prescribed by other clinics.

3.2. Use of Contraception. 230 women (28%) reported use of contraception at enrollment. The most common methods reported included the use of injectable hormones (52%), condoms (30%), and oral contraceptives (9%). Use of highly effective contraceptive methods was reported for 18% of the study subjects, two-thirds (65%) of those using contraception.

3.3. Bivariate and Multivariable Analysis. HIV disclosure was not associated with contraceptive use in bivariate or multivariable analyses. The variables significantly associated with the use of contraception in bivariate analyses were education, marital status, monthly income, having living children, and HIV status of spouse (Table 2).

In multivariable analysis, we found the odds of contraceptive use among single and previously married women remained significantly lower than that among married women (Table 2). Age (less than 24 years inclusive), education (completing secondary education), income (>250,000 Uganda shillings/month), and parity (having 3 or more living biological children) were independently associated with increased odds of contraception. HIV status of spouse was not significantly associated with contraceptive use in multivariable analysis; the association in bivariate analysis seemed to be due to colinearity with the marital status of the women. These associations remained significant in multivariable analysis using the multiple imputed dataset (data not shown). Additionally, women with one or two living biological children (versus none) had significantly increased odds of use of contraception using the imputed dataset.

We conducted a subanalysis of those reporting any contraception, to examine how condom use compared to other contraception methods (data not shown) within different variable groups. We found no significant difference in condom use versus other contraceptive use by HIV status disclosure ($P = 0.49$), or HIV status of spouse ($P = 0.59$).

4. Discussion

We found low contraceptive use (27.8%) among sexually active, not pregnant HIV-positive women enrolling at the ISS
| Demographic and behavioral characteristics among non-pregnant, sexually active women enrolling at ISS Clinic, Mbarara Uganda, during 2009. |
|--------------------------------------------------|
| **Total n (col%)** |
| All | 826 (100.0) |
| Demographics | |
| Age (years) (median (IQR)) | 29 (24–35) |
| 18–24 | 211 (25.5) |
| 25–29 | 206 (25.0) |
| 30–35 | 234 (28.3) |
| 36–39 | 175 (21.2) |
| Education | |
| None | 0 (0.0) |
| Primary level | 453 (54.8) |
| Secondary | 148 (17.9) |
| Tertiary | 64 (7.8) |
| Missing | 161 (19.5) |
| Marital status | |
| Married | 398 (48.5) |
| Previously married (separated, divorced, or widowed) | 348 (42.4) |
| Not married | 75 (9.1) |
| Tribe | |
| Kiga | 81 (9.8) |
| Nkole | 596 (72.2) |
| Other | 109 (13.2) |
| Missing | 40 (4.8) |
| Religion | |
| Catholic | 246 (29.8) |
| Protestant | 419 (50.7) |
| Muslim | 83 (10.0) |
| Other | 22 (2.7) |
| Missing | 56 (6.8) |
| Monthly income (USH) | |
| <100,000 | 575 (69.7) |
| 100,000–250,000 | 73 (8.8) |
| >250,000 | 16 (1.9) |
| Missing | 162 (19.6) |
| Among married persons: HIV status of spouse | |
| Negative | 21 (5.3) |
| Positive | 281 (70.6) |
| Unknown | 70 (17.6) |
| Missing | 26 (6.5) |
| Among married persons: HIV status disclosure | |
| Disclosed to spouse | 279 (70.1) |
| Disclosed to someone but not to spouse | 48 (12.6) |
| No disclosure reported | 71 (17.8) |
| Health status | |
| Among un-married persons: HIV status disclosure | |
| Disclosed to sexual partner | 13 (3.1) |
| Disclosed to others but not to sexual partner | 301 (71.2) |
| No disclosure reported | 109 (25.8) |
| CD4 cell count (/mm$^3$) | |
| ≤200 | 219 (26.5) |
| 201–350 | 149 (18.0) |
| 351–500 | 115 (14.0) |
| >500 | 205 (24.8) |
| Missing | 138 (16.7) |
| Number of living biological children | |
| 0 children | 39 (4.7) |
| 1-2 children | 208 (25.2) |
| 3 or more children | 186 (22.5) |
| Missing | 393 (47.6) |
| Type of contraceptive method used | |
| None | 596 (72.2) |
| Condoms | 68 (8.2) |
| Oral contraceptives | 20 (2.4) |
| Injectable hormones | 119 (14.4) |
| Norplant | 0 (0.0) |
| Natural family planning/rhythm method | 7 (0.9) |
| Intrauterine device | 1 (0.1) |
| Sterilization | 5 (0.6) |
| Diaphragm | 2 (0.2) |
| Other | 3 (0.4) |
| Condom use + another method | 5 (0.6) |

$^a$WHO clinical stage refers to the World Health Organization clinical staging for HIV disease based on symptoms, signs and diagnosed opportunistic infections in clients with HIV infection. Stages 1 and 2 are considered asymptomatic or mild disease, while stages 3 and 4 are considered severe disease and patients in these categories should begin antiretroviral therapy.

Clinic in Mbarara Hospital, consistent with contraception rates of the general Ugandan population [15], as well as HIV-positive women in Uganda [30, 31], Kenya, and Malawi [34]. The use of highly effective contraceptive methods was also low (18%), also consistent with the general Ugandan population [15] as well as those with HIV [20]. Thus, the low levels of contraceptive use in the sample may reflect the same root causes for low contraception uptake in Uganda, including insufficient information about the advantages of, fear of side effects from, and lack of access to contraception.
| Demographics                                      | Use of any contraception* | Adjusted Odds Ratio** | 95% Confidence Interval |
|--------------------------------------------------|---------------------------|-----------------------|-------------------------|
| All                                              | 596 (72.2)                | 230 (27.8)            |                         |
| **Demographics**                                 |                           |                       |                         |
| **Age at enrollment (years)**                    |                           |                       |                         |
| 18–24                                            | 148 (70.1)                | 63 (29.9)             | 1.00                    |
| 25–29                                            | 148 (71.8)                | 58 (28.2)             | 0.83 (0.51, 1.34)       |
| 30–35                                            | 163 (69.7)                | 71 (30.3)             | 0.89 (0.55, 1.43)       |
| 36–49                                            | 137 (78.3)                | 38 (21.7)             | 0.49 (0.28, 0.86)       |
| **Education**                                    |                           |                       |                         |
| Primary level                                    | 331 (73.1)                | 122 (26.9)            | 1.00                    |
| Secondary                                       | 93 (62.8)                 | 55 (37.2)             | 1.71 (1.10, 2.67)       |
| Tertiary                                        | 46 (71.9)                 | 18 (28.1)             | 0.91 (0.44, 1.88)       |
| Missing                                          | 126 (78.3)                | 35 (21.7)             | 0.80 (0.51, 1.26)       |
| **Marital status**                               |                           |                       |                         |
| Married                                          | 251 (63.1)                | 147 (36.9)            | 1.00                    |
| Previously married (separated, divorced, or widowed) | 279 (80.2)               | 69 (19.8)             | 0.50 (0.30, 0.82)       |
| Not married                                      | 62 (82.7)                 | 13 (17.3)             | 0.39 (0.18, 0.83)       |
| **Tribe**                                        |                           |                       |                         |
| Nkole                                            | 436 (73.2)                | 160 (26.8)            | 1.00                    |
| Kiga                                             | 52 (64.2)                 | 29 (35.8)             | 1.52 (0.89, 2.61)       |
| Other                                            | 80 (73.4)                 | 29 (26.6)             | 1.14 (0.67, 1.93)       |
| Missing                                          | 28 (70.0)                 | 12 (30.0)             | 0.84 (0.39, 1.82)       |
| **Religion**                                     |                           |                       |                         |
| Catholic                                         | 181 (73.6)                | 65 (26.4)             | 1.00                    |
| Protestant                                       | 300 (71.6)                | 119 (28.4)            | 1.07 (0.73, 1.57)       |
| Muslim                                           | 60 (72.3)                 | 23 (27.7)             | 0.89 (0.47, 1.70)       |
| Other                                            | 16 (72.7)                 | 6 (27.3)              | 1.16 (0.40, 3.37)       |
| Missing                                          | 39 (69.6)                 | 17 (30.4)             | 1.38 (0.69, 2.75)       |
| **Monthly income (USH)**                         |                           |                       |                         |
| <100,000                                         | 417 (72.5)                | 158 (27.5)            | 1.00                    |
| 100,000–250,000                                  | 50 (68.5)                 | 23 (31.5)             | 1.16 (0.64, 2.11)       |
| >250,000                                         | 6 (37.5)                  | 10 (62.5)             | 4.80 (1.48, 15.61)      |
| Missing                                          | 123 (75.9)                | 39 (24.1)             | 0.94 (0.61, 1.47)       |
| **HIV status of spouse/partner**                 |                           |                       |                         |
| Positive                                         | 183 (64.7)                | 100 (35.3)            | 1.00                    |
| Negative                                         | 9 (42.9)                  | 12 (57.1)             | 1.80 (0.69, 4.72)       |
| Unknown                                          | 40 (56.3)                 | 31 (43.7)             | 1.27 (0.71, 2.27)       |
| N/A: no spouse                                   | 343 (80.7)                | 82 (19.3)             |                         |
| Missing                                          | 21 (80.8)                 | 5 (19.2)              | 0.43 (0.15, 1.26)       |
| **HIV status disclosure**                        |                           |                       |                         |
| Disclosed to spouse/partner                       | 202 (64.5)                | 111 (35.5)            | 1.00                    |
| Disclosed to someone other than spouse/partner    | 259 (78.3)                | 72 (21.8)             | 0.93 (0.56, 1.54)       |
| No disclosure reported                           | 135 (74.2)                | 47 (25.8)             | 0.86 (0.53, 1.40)       |
| **Health status**                                |                           |                       |                         |
| WHO clinical stage                                |                           |                       |                         |
| Stage 1 or 2                                     | 365 (69.4)                | 161 (30.6)            | 1.00                    |
| Stage 3 or 4                                     | 157 (78.5)                | 43 (21.5)             | 0.72 (0.47, 1.10)       |
| Missing                                          | 74 (74.0)                 | 26 (26.0)             | 0.90 (0.53, 1.51)       |
In addition, some of these women may have wanted to have children [20, 23, 35] but our medical records did not capture this desire. Furthermore, some women who want to access contraception may be thwarted by the plans of her spouse or sexual partner [36, 37].

Among clients who reported use of contraception, more than half (52%) used hormonal injectable contraception, and 30% used condoms. Other studies conducted at HIV clinics in Uganda found that the most commonly reported contraception method is condom use [17, 20, 25]. The women in these other studies were either initiating or already on ART and thus may have already been in HIV care for some time with easier access to condoms and frequent exposure to counseling promoting condoms to prevent HIV transmission and pregnancy. In contrast, 70% of the women in our sample were recently diagnosed with HIV and only 7% were on ART. While the Uganda AIDS Control Program National guidelines advocate for dual family planning methods (condoms plus another contraceptive method) to prevent HIV/STI transmission and unintended pregnancies for HIV-positive individuals, only a small proportion used dual protection in this study (2%), consistent with other Ugandan studies [17, 20, 22, 38]. Use of condoms alone or dual contraception methods may have been low in our study; however, because 70% of married women reported having HIV-infected spouses, they therefore may have been less likely to use condoms to prevent sexual transmission of HIV. The high proportion of women choosing injectable hormonal contraception emphasizes the need to continue to unravel the relationship between hormonal contraception use and HIV risk [39, 40].

Our primary predictor variable of interest, HIV status disclosure, was not associated with use of contraception in either bivariate or multivariable analyses. Demographic factors (e.g. marital status, already having several children, younger age) and socioeconomic factors (e.g. education and income) were more strongly associated with contraception use at clinic entry. This is in contrast to a recent study in Uganda that showed that the lack of HIV disclosure was associated with lower odds of use of modern contraceptives among HIV women enrolled in HIV clinics in Uganda, in which 68% of the women were on ART [20]. In addition, we did not find any significant association between HIV status disclosure and use of condoms, in contrast to the findings of other studies [20, 28, 31, 32, 41]. Seventy percent of the married women in our study reported seroconcordant positive spouses, thus condoms to prevent HIV transmission may not be perceived to be applicable to this group. The observed association of decreased use of contraception with increased age was consistent with previous findings of lower modern contraceptive use among older women on ART in Zambia [41] and HIV-infected women in Uganda [20, 30]. Parity and education have also been associated with contraceptive use in other studies [28, 30, 34, 41, 42]. Younger age [22, 23, 43–46] and having fewer children [22, 24, 43, 46] are often associated with increased fertility desires and could thus be expected to be associated with decreased contraceptive use [34]. While the association of younger age with increased contraceptive use in our study is consistent with others, it is the opposite of what would be expected based on fertility desires. Older HIV-positive women may have a larger unmet need for contraception to limit childbearing, while younger women may have a larger unmet need to control spacing of births [15]. Given that many women in Uganda, especially those with HIV, face difficult economic and social circumstances [47] including bearing children whom they may raise as widows or divorced, the associations between contraception and education, as well as marital status and monthly income, are particularly important. The low use of contraception by women in this study, most of whom were recently diagnosed with HIV, points to the possibility that entry into HIV care could be a good time to intervene with contraception education and provision.

Our findings are limited by a high degree of missing data that is inherent to data collected as part of routine

### Table 2: Continued.

| CD4 count | No, n (%) | Yes, n (%) | Adjusted Odds Ratio** | 95% Confidence Interval |
|-----------|-----------|------------|-----------------------|-------------------------|
| >500      | 139 (67.8)| 66 (32.2)  | 1.00                  |                         |
| 351–500   | 78 (67.8) | 37 (32.2)  | 1.19                  | (0.70, 2.03)            |
| 201–350   | 111 (74.5)| 38 (25.5)  | 0.85                  | (0.51, 1.42)            |
| ≤200      | 161 (73.5)| 58 (26.5)  | 0.93                  | (0.58, 1.50)            |
| Missing   | 107 (77.5)| 31 (22.5)  | 0.71                  | (0.41, 1.24)            |

| Number of living biological children | No, n (%) | Yes, n (%) | Adjusted Odds Ratio** | 95% Confidence Interval |
|-------------------------------------|-----------|------------|-----------------------|-------------------------|
| 0 children                          | 33 (84.6) | 6 (15.4)   | 1.00                  |                         |
| 1-2 children                        | 143 (68.8)| 65 (31.2)  | 2.62                  | (0.99, 6.96)            |
| 3 or more children                 | 112 (60.2)| 74 (39.8)  | 4.26                  | (1.54, 11.75)           |
| Missing                             | 308 (78.4)| 85 (21.6)  | 1.84                  | (0.70, 4.84)            |

* Any contraception refers to self-reported use of one or more of the methods of contraception in Table 1.

** Estimates from logistic regression adjusting for all other variables in the table.
clinical care. However, the missing data categories were not associated with the use of contraception in the multivariable analysis, suggesting that the data were not missing systematically, and the results did not change when we performed multiple imputation. The data were collected by clinic counselors rather than by research assistants trained in systematic data collection and therefore may be especially subject to interviewer bias and social desirability bias or other types of response bias. In addition, these data do not account for desired pregnancy by the women and/or their partners [25, 28, 34, 48]. We also recognize that the cross sectional nature of this analysis focusing on contraceptive methods used at point of entry into HIV care does not allow inference about the method used at the time of HIV acquisition. In addition, the women served by the ISS clinic are a mixture of those from rural and urban areas; therefore, the findings may not fully translate to women enrolling in urban HIV clinics or those in very rural settings.

However, the strength of this study is that we were able to study a large number of HIV-infected women of reproductive age entering chronic HIV care, a population which may have had little previous exposure to health care and reproductive services. Our study highlights the need to establish cost effective strategies for lower income countries to improve the uptake of contraception among those infected with HIV who do not want to have children. We also found that dual methods of contraception were rarely used; therefore, contraception programs should also educate clients about the value of dual methods in order to prevent HIV/STI transmission to partners as well as to prevent unintended pregnancies. A study using the same database found an increasing incidence of pregnancies from 2006 to 2010 and the use of contraception was protective against pregnancy [49].

Given the low contraceptive use among HIV-infected women in this study, which is comparable to contraception rates among the general population of Ugandan women, we suggest that strategies to improve contraception uptake target all women. We found that demographic and economic factors were important in the uptake of contraception; therefore, as countries plan improvement strategies to enhance contraception uptake among those infected with HIV who do not want to have children. The strength of this study is that we were able to study a large number of HIV-infected women of reproductive age entering chronic HIV care, a population which may have had little previous exposure to health care and reproductive services. Our study highlights the need to establish cost effective strategies for lower income countries to improve the uptake of contraception among those infected with HIV who do not want to have children. We also found that dual methods of contraception were rarely used; therefore, contraception programs should also educate clients about the value of dual methods in order to prevent HIV/STI transmission to partners as well as to prevent unintended pregnancies. A study using the same database found an increasing incidence of pregnancies from 2006 to 2010 and the use of contraception was protective against pregnancy [49].

Given the low contraceptive use among HIV-infected women in this study, which is comparable to contraception rates among the general population of Ugandan women, we suggest that strategies to improve contraception uptake target all women. We found that demographic and economic factors were important in the uptake of contraception; therefore, as countries plan improvement strategies to enhance contraception uptake among those infected with HIV who do not want to have children. The strength of this study is that we were able to study a large number of HIV-infected women of reproductive age entering chronic HIV care, a population which may have had little previous exposure to health care and reproductive services. Our study highlights the need to establish cost effective strategies for lower income countries to improve the uptake of contraception among those infected with HIV who do not want to have children. We also found that dual methods of contraception were rarely used; therefore, contraception programs should also educate clients about the value of dual methods in order to prevent HIV/STI transmission to partners as well as to prevent unintended pregnancies. A study using the same database found an increasing incidence of pregnancies from 2006 to 2010 and the use of contraception was protective against pregnancy [49].

Further work is needed to determine whether this strategy is effective in reducing unintended pregnancies among HIV-positive women in care and reducing transmission of HIV.

Conflict of Interests

The authors declare that they have no competing interests. The funding source had no influence on study design, data collection and analysis, interpretation of the data, paper preparation, or decision to submit for publication.

Acknowledgments

This paper was supported by a Grant from the National Institutes of Health, University of California San Francisco-Gladstone Institute of Virology and Immunology Center for AIDS Research (P30 AI027763) and by the National Institutes of Health Grant 5R25MH064712. The authors would like to thank the counselors, nurses, clinicians and data officers in the ISS Clinic for their contributions in collecting this patients’ information.

References

[1] Global Report, “UNAIDS report on the Global AIDS Epidemic,” Tech. Rep., UNAIDS, Geneva, Switzerland, 2010.
[2] UNAIDS, “Report on the global HIV/AIDS epidemic,” Tech. Rep., UNAIDS, Geneva, Switzerland, 2008.
[3] D. Hubacher, I. Mavranzouli, and E. McGinn, “Unintended pregnancy in sub-Saharan Africa: magnitude of the problem and potential role of contraceptive implants to alleviate it,” Contraception, vol. 78, no. 1, pp. 73–78, 2008.
[4] World Health Organization, PMTCT Strategic Vision 2010–2015: Preventing Mother-to-Child Transmission of HIV to Reach the UNGASS and Millennium Development Goals, World Health Organization, Geneva, Switzerland, 2010.
[5] R. Wilcher, T. Petruney, H. W. Reynolds, and W. Cates, “From effectiveness to impact: contraception as an HIV prevention intervention,” Sexually Transmitted Infections, vol. 84, supplement 2, pp. ii54–ii60, 2008.
[6] N. Rutenberg and C. Baek, “Field experiences integrating family planning into programs to prevent mother-to-child transmission of HIV,” Studies in Family Planning, vol. 36, no. 3, pp. 235–245, 2005.
[7] W. Hladik, J. Stover, G. Esiru, M. Harper, and J. Tappero, “The contribution of family planning towards the prevention of vertical HIV transmission in Uganda,” PLoS ONE, vol. 4, no. 11, Article ID e7691, 2009.
[8] C. Richey and V. Setty, “Family planning choices for women with HIV,” Population Reports L, no. 15, pp. 1–23, 2007.
[9] H. W. Reynolds, B. Janowitz, R. Wilcher, and W. Cates, “Contraception to prevent HIV-positive births: current contribution and potential cost savings in PEPFAR countries,” Sexually Transmitted Infections, vol. 84, supplement 2, pp. ii49–ii53, 2008.
[10] G. E. Gray and J. A. McIntyre, “HIV and pregnancy,” British Medical Journal, vol. 334, no. 7600, pp. 950–953, 2007.
[11] Q. Abdool-Karim, C. AbouZahr, K. Dehne et al., “HIV and maternal mortality: turning the tide,” The Lancet, vol. 375, no. 9730, pp. 1948–1949, 2010.
[12] V. Black, S. Brooke, and M. F. Chersich, “Effect of human immunodeficiency virus treatment on maternal mortality at a
tertiary center in South Africa: a 5-year audit,” *Obstetrics and Gynecology*, vol. 114, no. 2, pp. 292–299, 2009.

[13] World Health Organization, *Reproductive Health Strategy to Accelerate Progress Towards the Attainment of International Development Goals and Targets*, World Health Organization, Geneva, Switzerland, 2004.

[14] World Health Organization, *Rapid Advice: Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants*, World Health Organization, Geneva, Switzerland, 2009.

[15] Uganda Bureau of Statistics (UBOS) and Macro International, *Uganda Demographic and Health Survey 2006*, Uganda Bureau of Statistics (UBOS) and Macro International, Calverton, Md, USA, 2007.

[16] Ministry of Health, *The Integrated National Guidelines on Antiretroviral Therapy, Prevention of Mother to Child Transmission of HIV, and Infant and Young Child Feeding*, Ministry of Health, Kampala, Uganda, 2011.

[17] J. Homsy, R. Bunnell, D. Moore et al., “Reproductive intentions and outcomes among women on antiretroviral therapy in rural Uganda: a prospective cohort study,” *PLoS ONE*, vol. 4, no. 1, Article ID e4149, 2009.

[18] R. King, K. Khana, S. Nakayiwa et al., “‘Pregnancy comes accidentally—like it did with me’: reproductive decisions among women on ART and their partners in rural Uganda,” *BMC Public Health*, vol. 11, article 530, 2011.

[19] S. R. Schwartz et al., “High incidence of unplanned pregnancy after antiretroviral therapy initiation: findings from a prospective cohort study in South Africa,” *PLoS ONE*, vol. 7, no. 4, Article ID e36039, 2012.

[20] R. K. Wanyenze, N. M. Tumwesigye, R. Kindyomunda et al., “Uptake of family planning methods and unplanned pregnancies among HIV-infected individuals: a cross-sectional survey among clients at HIV clinics in Uganda,” *Journal of the International AIDS Society*, vol. 14, no. 1, article 35, 2011.

[21] C. J. Chibwesha, M. J. Giganti, N. Putta et al., “Optimal time on HAART for prevention of mother-to-child transmission of HIV,” *Journal of Acquired Immune Deficiency Syndromes*, vol. 58, no. 2, pp. 224–228, 2011.

[22] J. Heys, W. Kipp, G. S. Jhangri, A. Alibhai, and T. Rubaale, “Fertility desires and infection with the HIV: results from a survey in rural Uganda,” *AIDS*, vol. 23, supplement 1, pp. S37–S45, 2009.

[23] M. Maier, I. Andia, N. Emenyounu et al., “Antiretroviral therapy is associated with increased fertility desire, but not pregnancy or live birth, among HIV+ women in an early HIV treatment program in rural Uganda,” *AIDS and Behavior*, vol. 13, supplement 1, pp. S28–S37, 2009.

[24] D. Cooper, J. Moodley, V. Zweigenthal, L. G. Bekker, I. Shah, and L. Myer, “Fertility intentions and reproductive health care needs of people living with HIV in Cape Town, South Africa: implications for integrating reproductive health and HIV care services,” *AIDS and Behavior*, vol. 13, supplement 1, pp. S38–S46, 2009.

[25] I. Andia, A. Kaida, M. Maier et al., “Highly active antiretroviral therapy and increased use of contraceptives among HIV-positive women during expanding access to antiretroviral therapy in Mbarara, Uganda,” *American Journal of Public Health*, vol. 99, no. 2, pp. 340–347, 2009.

[26] R. A. Hatcher, J. Trussell, A. L. Nelson et al., “Contraceptive efficacy,” in *Contraceptive Technology*, Ardent Media, New York, NY, USA, 19th Revised edition, 2007.
[42] A. A. A. Ali, D. A. Rayis, M. Mamoun, and I. Adam, “Use of family planning methods in Kassala, Eastern Sudan,” *BMC Research Notes*, vol. 4, article 43, 2011.

[43] L. Myer, C. Mronni, and K. Rebe, “Prevalence and determinants of fertility intentions of HIV-infected women and men receiving antiretroviral therapy in South Africa,” *AIDS Patient Care and STDs*, vol. 21, no. 4, pp. 278–285, 2007.

[44] J. Beyeza-Kashesya, A. M. Ekstrom, F. Kaharuza, F. Mirembe, S. Neema, and A. Kulane, “My partner wants a child: a cross-sectional study of the determinants of the desire for children among mutually disclosed sero-discordant couples receiving care in Uganda,” *BMC Public Health*, vol. 10, article 247, 2010.

[45] O. Kakaire, M. O. Osinde, and D. K. Kaye, “Factors that predict fertility desires for people living with HIV infection at a support and treatment centre in Kabale, Uganda,” *Reproductive Health*, vol. 7, no. 1, article 27, 2010.

[46] W. Kipp, J. Heys, G. S. Jhangri, A. Alibhai, and T. Rubaale, “Impact of antiretroviral therapy on fertility desires among HIV-infected persons in rural Uganda,” *Reproductive Health*, vol. 8, article 27, 2011.

[47] UGANDA: HIV-positive mums struggle to find safe food for their babies, [http://www.irinnews.org/Report/85032/UGANDA-HIV-positive-mums-struggle-to-find-safe-food-for-their-babies](http://www.irinnews.org/Report/85032/UGANDA-HIV-positive-mums-struggle-to-find-safe-food-for-their-babies), 2009.

[48] E. Maticka-Tyndale, “Condoms in sub-Saharan Africa,” *Sexual Health*, vol. 9, no. 1, pp. 59–72, 2012.

[49] J. Kabami and F. Bajunirwe, “Incidence and predictors of pregnancy among women receiving HIV care and treatment at a large urban facility in Western Uganda,” in *Proceedings of the 6th IAS Conference on HIV Pathogenesis*, Rome, Italy, 2011.

[50] USAID—Deliver Project—Contraceptive Security Indicators, [http://deliver.jsi.com/dhome/topics/monitoring/monitoring-pubs/meresources/memaps/meicsindicatorsmaps](http://deliver.jsi.com/dhome/topics/monitoring/monitoring-pubs/meresources/memaps/meicsindicatorsmaps), 2011.